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Abstract
Objective
To examine the safety and tolerability as well as the preliminary eﬃcacy of arimoclomol, a heat
shock protein co-inducer that promotes nascent protein folding, in patients with rapidly pro-
gressive SOD1 amyotrophic lateral sclerosis (ALS).
Methods
This was a double-blind, placebo-controlled trial in which patients with rapidly progressive SOD1-
mutant ALS were randomized 1:1 to receive arimoclomol 200 mg tid or matching placebo for up
to 12 months. Study procedures were performed using a mix of in-person and remote assess-
ments. Primary outcome was safety and tolerability. Secondary outcome was eﬃcacy, with
survival as the principal measure. Additional eﬃcacy measures were the rates of decline of the
Revised ALS Functional Rating Scale (ALSFRS-R) and percent predicted forced expiratory
volume in 6 seconds (FEV6), and the Combined Assessment of Function and Survival (CAFS).
Results
Thirty-eight participants were randomized. Thirty-six (19 placebo, 17 arimoclomol) were in-
cluded in the prespeciﬁed intent-to-treat analysis. Apart from respiratory function, groups were
generally well-balanced at baseline. Adverse events occurred infrequently, and were usually mild
and deemed unlikely or not related to study drug. Adjusting for riluzole and baseline ALSFRS-R,
survival favored arimoclomol with a hazard ratio of 0.77 (95% conﬁdence interval [CI]
0.32–1.80). ALSFRS-R and FEV6 declined more slowly in the arimoclomol group, with treat-
ment diﬀerences of 0.5 point/month (95% CI −0.63 to 1.63) and 1.24 percent predicted/month
(95% CI −2.77 to 5.25), respectively, and the CAFS similarly favored arimoclomol.
Conclusions
This study provides Class II evidence that arimoclomol is safe and well-tolerated at a dosage of
200 mg tid for up to 12months. Although not powered for therapeutic eﬀect, the consistency of
results across the range of prespeciﬁed eﬃcacy outcome measures suggests a possible thera-
peutic beneﬁt of arimoclomol.
Clinicaltrials.gov identifier
NCT00706147.
Classification of evidence
This study provides Class II evidence that arimoclomol is safe and well-tolerated at a dosage of
200 mg tid for up to 12 months. The study lacked the precision to conclude, or to exclude, an
important therapeutic beneﬁt of arimoclomol.
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Amyotrophic lateral sclerosis (ALS) is characterized by the
formation of cytosolic aggregates that contain speciﬁc
misfolded proteins in selected neuronal and glia cells.1
There is mounting evidence that these aggregates play
a pathogenic role in disease initiation and propagation.2,3
Mutations in the gene encoding CuZn-superoxide dis-
mutase (SOD1), the second most common identiﬁed
cause of ALS, make the SOD1 protein more prone to
aggregation, resulting in the deposition of cellular inclu-
sions that contain misfolded SOD1 aggregates.4 With
the goal of targeting the formation of such pathogenic
aggregates, we selected arimoclomol (CytRx, Los Angeles,
CA; and Orphazyme, Copenhagen, Denmark) for evalua-
tion in patients with rapidly progressive ALS caused by
SOD1 mutations. Arimoclomol is a co-inducer of the heat
shock protein (HSP) response5–7 and promotes natural
folding of nascent proteins and refolding of misfolded
proteins.8 Our choice of arimoclomol was further sup-
ported by evidence of meaningful therapeutic eﬀect in
methodologically rigorous studies in the G93A SOD1
mouse7,9; its good safety record (up to 300 mg/day) for
a short period of time (12 weeks) in patients with ALS; and
evidence of good penetration across the blood–brain
barrier.10
Since ALS is an etiologically, genetically, and phenotypi-
cally heterogeneous syndrome,11,12 we elected to focus
exclusively on patients with ALS with a subset of SOD1
mutations that result in unstable SOD1 proteins13 and are
associated with a uniformly rapid rate of disease pro-
gression.14 We were cognizant that rapid disease pro-
gression would yield both advantages (e.g., large degree of
measurable functional decline) and disadvantages (e.g.,
a highly aggressive form of disease might be most imper-
vious to therapeutic eﬀorts). We also recognized that the
rapid accumulation of physical disability could limit par-
ticipants’ ability to travel for study visits, and that re-
cruitment would be challenging for this ultrarare
population. For these reasons, this study was originally
proposed as an adaptive design, seamless, phase II/III,
randomized, double-blind, placebo-controlled trial, with
remote assessment of outcomes. The initial goals were to
show safety/tolerability (phase II) and then eﬃcacy (phase
III). Slow recruitment, however, necessitated an adminis-
trative decision to close the trial after completion of phase
II. Here we report the safety and eﬃcacy data from the
completed phase II component of this trial.
Methods
Standard protocol approvals, registrations,
and patient consents
Institutional review board (IRB) approval was obtained at
each study center, and all participants provided written in-
formed consent. The trial was registered on clinicaltrials.gov
(NCT00706147).
Study design and participants
This randomized, double-blind, placebo-controlled trial was
conducted at 2 sites and 3 academic medical centers in the
United States (primary site: Emory University [until February
2011] then University of Miami [from March 2011]; second
site: Massachusetts General Hospital [MGH]). An in-
dependent medical monitor completed regular review of
laboratory reports and adverse events (AEs), as well as real-
time review of serious AEs (SAEs). Eligibility criteria (table
e-1, links.lww.com/WNL/A135) aimed to enroll, from across
the United States and Canada, a population relatively early in
the course of ALS caused by SOD1mutations associated with
rapidly progressive disease.
Randomization and blinding
Randomization (1:1 to arimoclomol or matching placebo)
was stratiﬁed by riluzole use and in block size of 2 within each
stratum, and implemented using a central web-based elec-
tronic data capture (EDC) system managed by the Neuro-
logic Clinical Research Institute Data Management Center at
MGH. The randomization schedule, generated by a study
statistician (J.W.), was provided to each research pharmacy.
At randomization, the EDC assigned a participant identiﬁca-
tion number, which the site coordinator submitted to the
research pharmacy for drug dispensing. Encapsulated placebo
was matched in color and appearance to active drug. Except
for the research pharmacists, pharmacy monitors, and study
statisticians, all other personnel and study participants were
blinded to treatment assignments.
Procedures
Arimoclomol and matching placebo were prepared and
packaged by the CytRx Corporation (Los Angeles, CA). The
Glossary
AE = adverse event; ALS = amyotrophic lateral sclerosis; ALSFRS-R = Revised ALS Functional Rating Scale; CAFS =
Combined Assessment of Function and Survival; CI = conﬁdence interval; CTCAE = Common Terminology Criteria for
Adverse Events;DSMB =Data Safety Monitoring Board; EDC = electronic data capture; FEV6 = forced expiratory volume in 6
seconds; HR = hazard ratio; HSP = heat shock protein; IND = Investigational New Drug; IRB = institutional review board;
MGH =Massachusetts General Hospital; PAV = permanent assisted ventilation; SAE = serious adverse event; SOD1 = CuZn-
superoxide dismutase; SVC = slow vital capacity.
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research pharmacy of the primary site labeled and distributed
investigational product to the second study site. When the
ﬁrst participants were randomized (February 2009), the
highest dose permitted under the active Investigational New
Drug (IND) was 100 mg tid. InMay 2010, after enrollment of
the ﬁrst 16 participants (of whom 8 were on arimoclomol,
including 1 who was subsequently excluded per protocol), the
Food and Drug Administration approved the use of 200 mg
tid. Dosage was increased to this level for all active participants
(which for the arimoclomol group included 3 initially started
at 100 mg tid), and all newly enrolled participants received
200 mg tid after IRB approval of the revised protocol. All data
were analyzed following the intent-to-treat principle.
Knowing that participants, to be recruited across a broad geo-
graphic area, would accumulate physical disability quickly, we
anticipated the challenges that participants would face in order to
travel to a study site. By design, therefore, assessments were
performed in person only at baseline and month 2, with remote
assessments planned for all other visits. Neurologic examination,
motor unit number estimation, and slow vital capacity (SVC)
could only be performed in person. Other assessments, con-
ducted at all visits (in person and remotely), included vital signs;
blood and urine for safety laboratories; Revised ALS Functional
Rating Scale (ALSFRS-R), which has been validated for tele-
phone administration15; and the forced expiratory volume in 6
seconds (FEV6).16 In addition, AEs, concomitant medications,
study drug dosemanagement, use of ventilatory support, and key
study events were recorded at all visits.
Operationalization of remote assessments posed logistical
challenges that required the introduction of 2 innovative
features: (1) the collection of vital signs and blood/urine for
safety laboratories in participants’ homes: this was accom-
plished using the services of a mobile medical provider, Ex-
amination Management Services, Inc.; and (2) the use of
FEV6 as the principal measure of respiratory function: the key
advantage of FEV6 over SVC—and indeed, a necessity for
this study—is that FEV6 may be self-administered by the
participant using a low-cost portable device (Piko-6; nSpire
Health, Inc., Longmont, CO). The device digitally displayed
the FEV6 value, which the participant then reported to the
study coordinator. Our use of the FEV6 in this way allowed
for remote assessment of respiratory function, which we
would otherwise not have been able to collect in this trial.
Reproducibility and normative data for FEV6 are
established.17
Outcomes
The primary outcome measure was originally designated as
the ALSFRS-R rate of decline over 12 months, with survival
(deﬁned as permanent assisted ventilation [PAV] and
tracheostomy-free survival) and FEV6 rate of decline as sec-
ondary measures. Given the higher than expected mortality
observed in the combined groups in the blinded data, the
principal eﬃcacy measure was changed to survival in February
2014 with approval of the Data Safety Monitoring Board
(DSMB). Moreover, following the administrative decision to
close the trial early, safety became the designated primary
outcome, with eﬃcacy secondary. These revisions to the
protocol and statistical analysis plan were submitted under
IND 101,942.
The primary endpoint of safety and tolerability was based on
the frequency of AEs, abnormal vital signs, and abnormal
laboratory studies above or below predeﬁned alert levels. AEs
and SAEs were categorized according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) and rated for
severity and relatedness to study drug. In summarizing AEs:
(1) if a participant experienced multiple occurrences of the
same event, only the occurrence with the worst severity (or
highest degree of relatedness to study drug) was counted; (2)
CTCAE events were further classiﬁed into subgroups (AE
type); e.g., pneumonia and bronchitis were both classiﬁed as
upper/lower respiratory infection.
For eﬃcacy, the principal outcome measure was PAV- and
tracheostomy-free survival time, calculated from baseline to
PAV (deﬁned as ﬁrst of 7 consecutive days when PAV was
used >22 hours/d) or tracheostomy, date of death (if no PAV
or tracheostomy), or date of last available follow-up/study
contact (if still PAV- and tracheostomy-free by then). Par-
ticipants not reaching survival endpoints were censored.
Secondary eﬃcacy measures included ALSFRS-R rate of de-
cline (points/month), FEV6 rate of decline (% predicted/
month), and joint rank scores of the Combined Assessment of
Function and Survival (CAFS), which considers both
ALSFRS-R rate of decline and survival.
Sample size and statistical analyses
With insuﬃcient published data to establish a ﬁxed sample
size, we initially proposed a seamless adaptive design using
methods described by Fisher,18 with phase III sample size to
be re-estimated at the end of phase II, once the ﬁrst 30 par-
ticipants had completed at least 6 months of follow-up. The
phase II target sample size of 30 was based on our consider-
ation of the acceptable 6-month treatment failure rate in the
arimoclomol group, with treatment failure deﬁned as failure to
remain on the originally assigned treatment and dose due to
occurrence of an AE. Speciﬁcally, in the 15 arimoclomol
participants we would estimate the 80% conﬁdence interval
(CI) of their 6-month treatment failure rate, which was
expected to be <40% based on the preliminary estimate of
13.6% in a prior arimoclomol trial.10 The acceptance of such
a high rate of treatment failure (and wide CI) was justiﬁed by
the inexorably progressive nature of the disease and the ab-
sence of any known eﬀective therapy. We prespeciﬁed that we
would consider arimoclomol tolerable if the upper bound of
this CI was <40%. At the end of phase II, we were to utilize all
available data (up to 12 months of follow-up) to estimate the
number of additional participants needed in phase III in order
to detect, with 80% power and a 2-sided p = 0.05 signiﬁcance
level, a treatment diﬀerence of 30% based on ALSFRS-R rate
of decline, which was the diﬀerence deemed clinically
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meaningful and had been used in previous trials.19 The trial,
however, was closed before sample size re-estimation.
All 36 eligible participants who completed at least one follow-
up visit were included in the intent-to-treat analysis. The only
predeﬁned subgroup was the A4V SOD1 mutation carriers,
whom we expected to be the largest genetic subgroup and to
exhibit a uniformly aggressive disease course. An independent
DSMB performed periodic review of cumulative safety data
and made recommendations to the principal investigator re-
garding trial continuation.
PAV- and tracheostomy-free survival was ﬁrst summarized by
Kaplan-Meier survival estimates and compared between treat-
ment groups byWilcoxon and log-rank tests, then analyzed using
a proportional hazards model with riluzole use and baseline
ALSFRS-R as prespeciﬁed covariates. ALSFRS-R and FEV6
rates of decline were compared between groups by mixed model
analysis with a random intercept and slope, and the outcome
measure at each visit as dependent variable. The independent
variables were time and time–treatment interaction, with the test
of treatment eﬀect based on the time–treatment interaction. In
secondary analyses, a quadratic term for time was included, as
suggested by the ﬁnding of another ALS trial.20 In addition, 2
analyses that combine survival and ALSFRS-R rate of decline
were performed. The CAFS joint rank scores21 were compiled
for each participant and compared between groups by 2-sample t
test. Treatment eﬀect on the ALSFRS-R rate of decline, as well as
any treatment eﬀect on survival that is mediated through the
ALSFRS-R, were estimated by the Vonesh shared parameter
model.22 Numerical time, based on actual number of days be-
tween baseline and each follow-up visit, was used in the survival,
mixed model, and Vonesh analyses. For CAFS, survival times
and ALSFRS-R rates of decline were obtained using numerical
time, but the participant-to-participant comparisons made at
nominal time points. Baseline covariate adjustment for potential
imbalance between groups was considered. All analyses were
performed using SAS 9.3.
Role of the funding source
None of the funding sources played any role in the design,
analysis, or interpretation of data. The trial was conducted
under the auspice of an investigator-sponsored IND, refer-
encing the parent IND initially held by the CytRx Corpora-
tion and, after May 2011, by Orphazyme ApS (Copenhagen,
Denmark). Neither CytRx nor Orphazyme played any role in
trial design/implementation or in data analysis/publication.
Results
Participants
Enrollment was open between December 2008 and June
2014. The administrative decision to close the trial early
Figure 1 Consort diagram
There were 2 patients in the arimoclomol groupwhowere excluded from the intent-to-treat (ITT) analysis based on prespecified criteria: 1 patient died before
completion of the month 1 visit; the other was found, after randomization, not to have a mutation in the SOD1 gene. The 1 patient in the arimoclomol group
whowas censored atmonth 5 had stopped drug atmonth 2 because of a skin rash thought probably related to study drug, andwas then followed untilmonth
5, when the participant enrolled in another clinical trial. PAV = permanent assisted ventilation.
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Table 1 Patient characteristics
All patients (n = 36) A4V patients only (n = 26)
Placebo (n = 19) Arimoclomol (n = 17) Placebo (n = 13) Arimoclomol (n = 13)
Age, y
Mean ± SD 50.8 ± 10.3 51.1 ± 12.3 48.4 ± 10.3 52.8 ± 13.2
Median (range) 52 (25–65) 50 (29–75) 51 (25–62) 55 (29–75)
Sex
Male 7 6 6 4
Female 12 11 7 9
SOD1mutation
A4V 13 13 13 13
G85R 0 1 — —
G141X 1 0 — —
I113T 4 0 — —
V14G 1 0 — —
V148G 0 3 — —
Site of onset
Limb 16 15 11 12
Bulbar 1 2 1 1
Thoracic 2 0 1 0
Racea
White 19 17 13 13
Black/African American 0 0 0 0
Asian 0 0 0 0
Native American 1 0 1 0
Unknown 0 0 0 0
Ethnicity
Non-Hispanic or Latino 19 17 13 13
Highest level of education completed
High school 5 4 4 4
2-Year college 5 1 3 1
4-Year college 5 5 4 3
Master’s 3 7 1 5
Doctoral 1 0 1 0
Months from onset to randomizationb
Mean ± SD 8.0 ± 3.6 6.6 ± 3.3 8.5 ± 4.0 6.5 ± 3.5
Median (range) 8.1 (2.7–14.2) 6.1 (1.7–13.4) 8.4 (2.7–14.2) 6.1 (1.7–13.4)
ΔFRSb
Mean ± SD 1.24 ± 0.93 1.44 ± 1.30 1.41 ± 1.00 1.70 ± 1.38
Median (range) 0.80 (0.00–3.23) 0.94 (0.15–4.57) 1.17 (0.00–3.23) 1.46 (0.32–4.57)
Continued
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was made by the steering committee, with input from the
DSMB, while blinded to treatment group and study
results. A total of 89 patients were screened, and 38 ran-
domized (19/group). The absence of an SOD1 mutation
(n = 18) and the presence of an ineligible SOD1 mutation
(n = 8) were the most common reasons for ineligibility.
The 38 randomized were recruited at Emory (n = 15),
University of Miami (n = 13), and MGH (n = 10). Per
protocol, 2 participants were excluded from analysis; one
did not have an eligible SOD1 mutation and the other
completed no follow-up visits after baseline (ﬁgure 1).
Exclusions were made before unblinding, and both later
revealed to be in the arimoclomol group. The analysis
dataset thereby comprised 19 (53%) participants on
placebo and 17 (47%) participants on arimoclomol.
Groups were balanced at baseline except that FEV6 and
SVC were higher in the arimoclomol group, while body
mass index was higher in the placebo group (table 1).
Baseline SVC and FEV6 were strongly correlated (r = 0.89,
p < 0.0001).
Safety
AEs occurring in ≥10% (n ≥ 4) of participants are summarized
in table 2. These were generally mild, occurred with similar
frequency in the 2 arms, and were largely considered un-
related to study drug. Twenty-two SAEs were reported (15 in
the placebo and 7 in the arimoclomol group), none of which
were considered related to study drug. Abnormal vital signs or
laboratory values were infrequent and occurred with compa-
rable frequency in the 2 groups (table e-2, links.lww.com/
WNL/A135). A single participant stopped arimoclomol be-
cause of a skin rash (probably related to study drug).
Efficacy
While none of the eﬃcacy analyses yielded statistically signiﬁcant
results, all point estimates favored arimoclomol but with CIs
Table 1 Patient characteristics (continued)
All patients (n = 36) A4V patients only (n = 26)
Placebo (n = 19) Arimoclomol (n = 17) Placebo (n = 13) Arimoclomol (n = 13)
Months from diagnosis to randomization
Mean ± SD 3.1 ± 2.3 2.7 ± 2.1 2.8 ± 1.7 2.7 ± 2.3
Median (range) 2.3 (0.0–8.9) 2.4 (0.0–6.9) 3.1 (0.0–5.5) 2.0 (0.0–6.9)
Taking riluzole
Yes 11 11 7 10
No 8 6 6 3
Baseline ALSFRS-R (total score)
Mean ± SD 37.2 ± 8.2 39.5 ± 7.3 37.0 ± 7.8 38.0 ± 7.7
Median (range) 38 (17–48) 42 (21–47) 38 (17–48) 39 (21–47)
Baseline FEV6c (%predicted)
Mean ± SD 69.3 ± 28.5 78.2 ± 25.1 73.4 ± 33.1 81.5 ± 22.6
Median (range) 58.5 (31–110) 89 (23–115) 77.5 (31–110) 89 (33–115)
Baseline SVC (% predicted)
Mean ± SD 78.5 ± 25.3 91.2 ± 22.7 82.5 ± 27.1 90.3 ± 24.5
Median (range) 77 (38–119) 96 (37–124) 79 (38–119) 96 (37–124)
Baseline BMI,d kg/m2
Mean ± SD 28.4 ± 5.3 25.1 ± 3.5 29.3 ± 4.5 25.5 ± 3.1
Median (range) 29.7 (19.2–35.9) 25.0 (18.1–30.5) 29.7 (21.6–34.6) 25.5 (21.6–30.5)
Abbreviations: ALSFRS-R = Revised ALS Functional Rating Scale; BMI = body mass index; FEV6 = forced expiratory volume in 6 seconds; SVC = slow vital
capacity.
ΔFRS = (48 − ALSFRS-R at randomization)/months from onset to randomization.
a Multiple categories possible.
b Months from onset to randomization (and therefore ΔFRS) were not formally collected in the trial; they were later abstracted frommedical records prior to
unblinding andwere unavailable for 2 patients on placebo. In addition,months fromonset to randomization and ΔFRS of 2 other patients on placebo (1 A4V, 1
non-A4V) were excluded due to extreme and questionable values (>30months). With those 2 outliers included:months from onset to randomization, mean ±
SD (median [range]) = 10.9 ± 8.9 (8.7 [2.7–35.2]) for all placebo, 10.4 ± 7.5 (8.7 [2.7–30.0]) for A4V placebo. ΔFRS, mean ± SD (median [range]) = 1.17 ± 0.90 (0.78
[0.00–3.23]) for all placebo, 1.32 ± 1.00 (1.03 [0.00–3.23]) for A4V placebo.
c Baseline FEV6 not available for one patient on placebo.
d Baseline weight (and therefore BMI) not available for one patient on arimoclomol.
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Table 2 Common Terminology Criteria for Adverse Events
Adverse event type
Any occurrence, n (%) SAE, n By grade, n By relationship to study drug, n
Placebo
(n = 19)
Arimoclomol
(n = 17)
Placebo
(n = 19)
Arimoclomol
(n = 17)
Placebo Arimoclomol Placebo Arimoclomol
1–2 3 4–5 1–2 3 4–5
Not/
unlike Possible Probable
Not/
unlike Possible Probable
Dyspnea (shortness of breath) 15 (79) 13 (76) 8 7 2 4 9 2 1 10 15 — — 13 — —
Respiratory: upper/lower 12 (63) 6 (35) 2 — 10 2 — 6 — — 12 — — 6 — —
Upper gastrointestinal: nausea/
anorexia/vomiting/duodenal ulcer
9 (47) 8 (47) 1 — 7 2 — 8 — — 9 — — 4 2 2
Muscle weakness: extremity/trunk/
generalized
7 (37) 8 (47) 1 — 4 2 1 3 4 1 7 — — 8 — —
Pain (other than headache) 7 (37) 7 (41) — — 4 3 — 4 3 — 6 1 — 7 — —
Lower gastrointestinal: diarrhea/
constipation
5 (26) 7 (41) — — 5 — — 7 — — 3 2 — 5 2 —
Mood: anxiety/depression/agitation 9 (47) 1 (6) — — 9 — — — 1 — 9 — — 1 — —
Headache 7 (37) 2 (12) — — 5 1 1 2 — — 5 2 — 1 1 —
Dysphagia (difficult swallowing) 5 (26) 3 (18) 3 — 1 4 — — 3 — 5 — — 3 — —
Fall 4 (21) 4 (24) — — 3 1 — 4 — — 4 — — 4 — —
Infection (other than respiratory) 5 (26) 2 (12) — — 5 — — 2 — — 5 — — 2 — —
Insomnia 3 (16) 4 (24) — — 3 — — 3 1 — 3 — — 4 — —
Saliva: dry month/sialorrhea/thick 3 (16) 4 (24) — — 3 — — 4 — — 2 1 — 3 1 —
Limb edema 1 (5) 4 (24) — — 1 — — 4 — — 1 — — 4 — —
Diaphoresis (sweating) 3 (16) 1 (6) — — 3 — — 1 — — 1 2 — 1 — —
Abbreviations: Not/unlike = not related or unlikely to be related; SAE = serious adverse event.
n = Number of patients with at least one occurrence of the adverse event type. If a patient experienced multiple occurrences of an adverse event type, the occurrence with the worst grade and strongest relationship to study
drug is used in the table.
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spanning unity. Kaplan-Meier plot shows a separation in survival
curves, though the curves slightly crossed around 7.5 months
(Wilcoxon test p = 0.27, log-rank test p = 0.33) (ﬁgure 2A).
Similar results are observed in the A4V subgroup (13/group)
(ﬁgure 2B). Survival estimates from the Cox proportional haz-
ards model also favored arimoclomol compared to control, with
an unadjusted hazard ratio (HR) of 0.67 (95%CI 0.29–1.48, p =
0.33); adjusting for baseline ALSFRS-R and riluzole, HR 0.77
(95% CI 0.32–1.80, p = 0.55). Adjustment for the baseline im-
balance in respiratory function did not aﬀect results (table e-3,
links.lww.com/WNL/A135).
Among placebo-treated participants, ALSFRS-R declined by
an average (±SE) of 3.0 ± 0.4 points/month, compared to 2.5
± 0.4 points/month in the arimoclomol-treated group,
a treatment diﬀerence of 0.5 points/month (95% CI −0.63 to
1.63, p = 0.37). In the A4V subgroup, ALSFRS-R declined
even faster, by an average of 3.6 ± 0.5 points/month in the
placebo group but only 2.6 ± 0.5 points/month in the ari-
moclomol group, a treatment diﬀerence of 0.98 points/month
(95% CI −0.28 to 2.24, p = 0.12). Notably, the magnitude of
this diﬀerence is comparable to the average ALSFRS-R rate of
decline in the untreated general ALS population (1.02 ± 2.3
points/month).23 Moreover, the treatment diﬀerence of
0.5–1.0 points/month in ALSFRS-R rate of decline, though
not statistically signiﬁcant, translates into a clinically mean-
ingful diﬀerence of 6–12 points over a 1-year period. Similar
results were observed for the FEV6% predicted rate of decline
(table 3). Moreover, while adjustment for baseline ALSFRS-R
or respiratory function variably increased or decreased the
magnitude of treatment eﬀect, overall results were unchanged
(table e-3, links.lww.com/WNL/A135).
For the CAFS, which weights mortality as the more clinically
important outcome and whose rank scores range from 1
(worst) to 36 (best), the average (±SE) score in the arimo-
clomol group was 20.9 ± 2.5 compared to 16.3 ± 2.4 in the
placebo group, with a potential treatment beneﬁt of 4.57
points (95% CI −2.50 to 11.64) (table 3). Moreover, in
participant-to-participant comparison between the 2 groups,
the arimoclomol group had a clinically signiﬁcant win ratio of
1.69.24 The Vonesh model, on the other hand, yielded
a treatment diﬀerence of 0.77 ± 0.54 points/month (95% CI
−0.33 to 1.86, p = 0.16) in ALSFRS-R rate of decline, whereas
the direct eﬀect of treatment on survival was not signiﬁcant (p
= 0.62). This would indicate that the possible survival beneﬁt
of arimoclomol was mediated through a slowed decline of the
ALSFRS-R rather than through an independent eﬀect on
survival.
Discussion
Arimoclomol was safe and well-tolerated at a dose of 200 mg
tid. While not powered to detect a statistically signiﬁcant
therapeutic eﬀect, the consistency of results across all pre-
speciﬁed eﬃcacy measures suggests a possible therapeutic
beneﬁt of arimoclomol in the overall study population and
especially in the A4V subgroup.
We do not interpret these results as showing eﬃcacy, but are
encouraged by the strength and consistency of these pre-
liminary ﬁndings. Moreover, this trial is signiﬁcant in 3 other
respects. (1) It represents the ﬁrst ALS trial initiated in a ge-
netically and phenotypically homogeneous population.
Figure 2 Permanent assisted ventilation (PAV)– and tracheostomy-free survival
(A) All arimoclomol- and placebo-treated participants. At 12 months, 34% of arimoclomol-treated and <21% of placebo-treated participants were alive (and
without PAV or tracheostomy). (B) The subgroup of A4V participants. At 12months, 29%of arimoclomol-treated and 15%of placebo-treated participantswere
alive (and without PAV or tracheostomy).
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Although logistically challenging, this approach is both feasible
and highly relevant to future trials, as we increasingly recognize
the importance of targeting drugs with particular mechanisms of
action to patient subpopulations most likely to beneﬁt. (2) This
trial pioneered an approach in which safety and eﬃcacy assess-
ments relied heavily on remote assessments. This key design
feature helped tomitigate the physical burden of travel to a study
center, which can be a major barrier to trial participation. We
have also introduced FEV6 to the ALS ﬁeld and demonstrated its
usefulness in reliably quantifying respiratory function; FEV6may
be a useful alternative to vital capacity when the latter cannot
readily be obtained. (3) This trial provides the ﬁrst prospectively
acquired natural history data that inform survival in the mutant
SOD1 population. Among the placebo-treated patients, median
survival from diagnosis was 11.1 months (95% CI 6.5–13.5) for
all SOD1 mutations, and 9.3 months (95% CI 6.1–12.5) in the
A4V subgroup. Similarly, median survival from baseline was 7.4
months (95% CI 3.0–10.7) and 7.2 months (95% CI 2.9–10.5),
respectively. These estimates are of particular relevance to future
therapeutic studies. Moreover, median disease duration (time
from symptom onset to survival endpoint) was 17.5 months
(95%CI 11.6–18.4) among all placebo-treated patients, and 13.0
months (95% CI 6.3–21.3) in the A4V population; these data
lend weight to estimates of disease duration based on retro-
spectively collected data.14,25
An important limitation of this trial is the small sample size,
which was a function of the ultrarare population targeted for
enrollment. We estimate that at most 320 patients across the
entire United States could have been considered for the trial over
its planned 5-year duration, and this was assuming that all
patients would be willing to participate, and without accounting
for other eligibility criteria. Moreover, while this study was on-
going, 2 other trials targeting the mutant SOD1 population were
also recruiting.26,27 Although we successfully enrolled >10% of
the theoretically eligible population, it was insuﬃcient to permit
completion of the planned phase III component of the trial.
The absence of wet biomarker data is another limitation. This
reﬂects the logistical complexity and cost that would have
been required to collect, process, and store biological samples
from patients who were largely evaluated remotely. Growing
interest in developing methods or devices for remote collec-
tion of biomarker data might help to mitigate such challenges
in future trials.
These data support further development of arimoclomol as
a potential therapeutic for ALS. Critical to the design of the
next study will be the incorporation of potential pharmaco-
dynamic biomarkers, including those that might show target
engagement (e.g., upregulation of HSP). Moreover, it will be
essential to explore the use of a higher dose of arimoclomol
and to broaden the eligibility criteria to include a more diverse
population of patients with ALS, since arimoclomol’s mech-
anism of action is likely to be relevant to all forms of ALS, in
which aberrant proteostasis plays an essential role in disease
pathophysiology.
Author contributions
Michael Benatar, MD, PhD, served as the principal in-
vestigator and the site investigator at Emory and University of
Miami. He conceived, designed, obtained funding for, and
implemented the study. He assisted with results in-
terpretation, prepared the initial draft of the manuscript, and
critically edited it for publication. JoanneWuu, ScM, served as
coinvestigator and study statistician. She assisted in the design
and implementation of the trial and, together with David
Schoenfeld, PhD, was responsible for analysis of data. She
critically reviewed and edited the manuscript. Peter M.
Andersen, MD, PhD, performed SOD1 mutation testing and
critically reviewed the manuscript for content. Nazem Atassi,
MD, served as the site investigator for the trial at the Mas-
sachusetts General Hospital. He critically reviewed the man-
uscript for content. William David, MD, performed motor
unit number estimation at the MGH site. He critically
reviewed the manuscript for content. Merit Cudkowicz, MD,
served as co–principal investigator on the FDA grant appli-
cation and served on the trial steering committee. She criti-
cally reviewed the manuscript for content. David Schoenfeld,
PhD, was principally responsible for the design of the trial and
Table 3 Efficacy outcomes
All patients (n = 36) A4V patients only (n = 26)
Placebo
(n = 19)
Arimoclomol
(n = 17)
Treatment
differencea
Placebo
(n = 13)
Arimoclomol
(n = 13)
Treatment
differencea
ALSFRS-R slope (points per month) −3.0 ± 0.4 −2.5 ± 0.4 0.50 (−0.63, 1.63) −3.6 ± 0.5 −2.6 ± 0.5 0.98 (−0.28, 2.24)
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Study question
Is arimoclomol safe and tolerable, and is there preliminary
evidence of eﬃcacy, among patients with rapidly progressive
SOD1 amyotrophic lateral sclerosis (ALS)?
Summary answer
Arimoclomol is safe and tolerable at a dose of 200mg 3 times daily
(TID) for 12 months. Preliminary eﬃcacy data support further
development of arimoclomol as a potential ALS therapeutic.
What is known and what this article adds
This study provides further evidence (Class II) that arimo-
clomol is safe and tolerable and provides preliminary evidence
of eﬃcacy. It also successfully demonstrates the utility of re-
mote assessment methods.
Participants and setting
This study examined 36 adult patients (23women, 13men)with
rapidly progressive SOD1 ALS who were enrolled at 3 US aca-
demic medical centers between December 2008 and June 2014.
Design, size, and duration
For this double-blind trial with block randomization and
computer-generated allocation, participants were assigned to
receive arimoclomol (n = 17) or a placebo (n = 19) for up to
12 months. Arimoclomol or matched placebo was dispensed
in 200-mg TID doses.
Outcomes
Primary outcomes were safety and tolerability, assessed based
on frequencies of adverse events, abnormal vital signs, and
abnormal laboratory test results throughout the study period.
Secondary outcomes included survival and the rate of decline
of the revised ALS Functional Rating Scale.
Main results and the role of chance
Arimoclomol was safe and well-tolerated (table), with only
one participant stopping arimoclomol due to a (probably
related) skin rash. Point estimates of eﬃcacy outcomes all
favored arimoclomol, but with broad conﬁdence intervals,
precluding any ﬁrm conclusions about treatment beneﬁts.
Bias, confounding, and other reasons
for caution
This study was not powered for eﬃcacy outcomes. The wide
conﬁdence intervals around point estimates of eﬃcacy out-
come are likely due to small sample size.
Generalizability to other populations
Safety data are likely to be broadly relevant. While generaliz-
ability of the preliminary eﬃcacy results to non-SOD1 and more
slowly progressive ALS is less clear, further study in these pop-
ulations is supported by arimoclomol’s mechanism of action.
Study funding/potential competing interests
This study was funded by the ALS Association and the US
Food and Drug Administration, with additional support from
the Nordic ALS patient organizations, the Swedish Brain
Research Foundation, and the Knut and Alice Wallenberg
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pharmaceutical companies and personal compensation from
various pharmaceutical companies and the Remedys Foun-
dation Switzerland. Go to Neurology.org/N for full
disclosures.
Table 1
Serious Adverse Event
No. in placebo
group
No. in arimoclomol
group
Dyspnea 8 7
Respiratory disorders 2 –
Upper gastrointestinal
disorders
1 –
Muscle weakness 1 –
Dysphagia 3 –
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